Biochemistry, genetics and therapy of malignant pheochromocytomas

Annales d'Endocrinologie

Volumn 70, Issue 3, 2009, Pages 166-167

  Mannelli, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LANREOTIDE IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LANREOTIDE Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE Y 90; CATECHOLAMINE; CHROMOGRANIN A; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; ENOLASE; ETOPOSIDE; GELDANMYCIN; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE; THALIDOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; BIOCHEMISTRY; DISEASE COURSE; GENETIC SUSCEPTIBILITY; GENETICS; PHEOCHROMOCYTOMA; SCINTIGRAPHY; SURVIVAL RATE; SURVIVAL TIME;

EID: 67349139871     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2009.02.009     Document Type: Article

References (13)

1. H. Ahlman Malignant pheochromocytoma: state of the field with future projections Ann N Y Acad Sci 1073 2006 449 464
2. L. Amar A. Servais A.P. Gimenez-Roqueplo F. Zinzindohoue G. Chatellier Plouin PF Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma J Clin Endocrinol Metab 90 2005 2110 2116
3. S.D. Averbuch C.S. Steakley R.C. Young E.P. Gelmann D.S. Goldstein R. Stull Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine Ann Intern Med 109 1988 267 273
4. A. Chrisoulidou G. Kaltsas I. Ilias Grossman AB The diagnosis and management of malignant phaeochromocytoma and paraganglioma Endocr Relat Cancer 14 2007 569 585
5. J. Favier P.F. Plouin P. Corvol J.M. Gasc Angiogenesis Vascular architecture in pheochromocytomas: distinctive traits in malignant tumors Am J Pathol 161 2002 1235 1246
6. G.J. Förster M.J. Engelbach J.J. Brockmann H.J. Reber H.G. Buchholz H.R. Mäcke Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide Eur J Nucl Med 28 2001 1743 1750
7. M.H. Kulke K. Stuart P.C. Enzinger D.P. Ryan J.W. Clark A. Muzikansky Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors J Clin Oncol 9 24 2006 401 406
8. A. Morabito E. De Maio M. Di Maio N. Normanno F. Perrone Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions Oncologist 11 2006 753 764
9. H.P. Neumann C. Pawlu M. Peczkowska B. Bausch S.R. McWhinney M. Muresan Eng C Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations JAMA 292 8 2004 943 951
10. T. Scholz G. Eisenhofer K. Pacak H. Dralle H. Lehnert Clinical review: current treatment of malignant pheochromocytoma J Clin Endocrinol Metab 92 2007 1217 1225
11. W.T. Shen C. Sturgeon O.H. Clark Q.Y. Duh E. Kebebew Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas Surgery 136 2004 1129 1137
12. J.C. Sisson Radiopharmaceutical treatment of pheochromocytomas Ann N Y Acad Sci 970 2002 54 60
13. L.D. Thompson Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases Am J Surg Pathol 26 2002 551 566